EAN
HRTX icon

Excelsior Advisor Network’s Heron Therapeutics HRTX Stock Holding History

Excelsior Advisor Network’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
405,777
+120,168
+42% +$96.4K 0.02% 447
2026
Q1 		$229K Buy
+285,609
New +$331K 0.09% 193

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Excelsior Advisor Network's HRTX Position: Q2 2026 in Review

Excelsior Advisor Network increased its Heron Therapeutics (HRTX) stake by 42% in Q2 2026, buying an estimated $96.4K and bringing the position to 405,777 shares worth $173K. The position accounts for 0.02% of the portfolio, ranked #447.

Excelsior Advisor Network first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $229K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Excelsior Advisor Network held 405,777 shares of Heron Therapeutics worth $173K as of Q2 2026.
  • Excelsior Advisor Network bought 120,168 Heron Therapeutics shares in Q2 2026, an estimated $96.4K.
  • Heron Therapeutics made up 0.02% of Excelsior Advisor Network's portfolio in Q2 2026, its #447 holding.
  • Excelsior Advisor Network first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Excelsior Advisor Network's Heron Therapeutics position peaked at $229K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Excelsior Advisor Network's 13F filing for Q2 2026, filed 14 Aug 2026.